Koenraad R P Veys1,2, Mohamed A Elmonem3, Maria Van Dyck1, Mirian C Janssen4, Elisabeth A M Cornelissen5, Katharina Hohenfellner6, Giusi Prencipe7, Lambertus P van den Heuvel2,5, Elena Levtchenko8,2. 1. Division of Pediatric Nephrology, Department of Pediatrics, University Hospitals Leuven, Leuven, Belgium. 2. Department of Development and Regeneration, Katholieke Universiteit Leuven, Leuven, Belgium. 3. Department of Clinical and Chemical Pathology, Faculty of Medicine, Cairo University, Cairo, Egypt. 4. Department of Internal Medicine, Radboud University Medical Center, Nijmegen, The Netherlands. 5. Department of Pediatric Nephrology, Radboud University Medical Center, Nijmegen, The Netherlands. 6. Department of Pediatrics, Children's Hospital of Rosenheim, Rosenheim, Germany. 7. Division of Rheumatology and Immuno-Rheumatology Research Laboratories, Bambino Gesù Children's Hospital, Rome, Italy. 8. Division of Pediatric Nephrology, Department of Pediatrics, University Hospitals Leuven, Leuven, Belgium elena.levtchenko@uzleuven.be.
Abstract
BACKGROUND: Nephropathic cystinosis, a hereditary lysosomal storage disorder caused by dysfunction of the lysosomal cotransporter cystinosin, leads to cystine accumulation and cellular damage in various organs, particularly in the kidney. Close therapeutic monitoring of cysteamine, the only available disease-modifying treatment, is recommended. White blood cell cystine concentration is the current gold standard for therapeutic monitoring, but the assay is technically demanding and is available only on a limited basis. Because macrophage-mediated inflammation plays an important role in the pathogenesis of cystinosis, biomarkers of macrophage activation could have potential for the therapeutic monitoring of cystinosis. METHODS: We conducted a 2-year prospective, longitudinal study in which 61 patients with cystinosis who were receiving cysteamine therapy were recruited from three European reference centers. Each regular care visit included measuring four biomarkers of macrophage activation: IL-1β, IL-6, IL-18, and chitotriosidase enzyme activity. RESULTS: A multivariate linear regression analysis of the longitudinal data for 57 analyzable patients found chitotriosidase enzyme activity and IL-6 to be significant independent predictors for white blood cell cystine levels in patients of all ages with cystinosis; a receiver operating characteristic analysis ranked chitotriosidase as superior to IL-6 in distinguishing good from poor therapeutic control (on the basis of white blood cell cystine levels of <2 nmol 1/2 cystine/mg protein or ≥2 nmol 1/2 cystine/mg protein, respectively). Moreover, in patients with at least one extrarenal complication, chitotriosidase significantly correlated with the number of extrarenal complications and was superior to white blood cell cystine levels in predicting the presence of multiple extrarenal complications. CONCLUSIONS: Chitotriosidase enzyme activity holds promise as a biomarker for use in therapeutic monitoring of nephropathic cystinosis.
BACKGROUND:Nephropathic cystinosis, a hereditary lysosomal storage disorder caused by dysfunction of the lysosomal cotransporter cystinosin, leads to cystine accumulation and cellular damage in various organs, particularly in the kidney. Close therapeutic monitoring of cysteamine, the only available disease-modifying treatment, is recommended. White blood cell cystine concentration is the current gold standard for therapeutic monitoring, but the assay is technically demanding and is available only on a limited basis. Because macrophage-mediated inflammation plays an important role in the pathogenesis of cystinosis, biomarkers of macrophage activation could have potential for the therapeutic monitoring of cystinosis. METHODS: We conducted a 2-year prospective, longitudinal study in which 61 patients with cystinosis who were receiving cysteamine therapy were recruited from three European reference centers. Each regular care visit included measuring four biomarkers of macrophage activation: IL-1β, IL-6, IL-18, and chitotriosidase enzyme activity. RESULTS: A multivariate linear regression analysis of the longitudinal data for 57 analyzable patients found chitotriosidase enzyme activity and IL-6 to be significant independent predictors for white blood cell cystine levels in patients of all ages with cystinosis; a receiver operating characteristic analysis ranked chitotriosidase as superior to IL-6 in distinguishing good from poor therapeutic control (on the basis of white blood cell cystine levels of <2 nmol 1/2 cystine/mg protein or ≥2 nmol 1/2 cystine/mg protein, respectively). Moreover, in patients with at least one extrarenal complication, chitotriosidase significantly correlated with the number of extrarenal complications and was superior to white blood cell cystine levels in predicting the presence of multiple extrarenal complications. CONCLUSIONS: Chitotriosidase enzyme activity holds promise as a biomarker for use in therapeutic monitoring of nephropathic cystinosis.
Authors: Y Guo; W He; A M Boer; R A Wevers; A M de Bruijn; J E Groener; C E Hollak; J M Aerts; H Galjaard; O P van Diggelen Journal: J Inherit Metab Dis Date: 1995 Impact factor: 4.982
Authors: Craig B Langman; Bruce A Barshop; Georges Deschênes; Francesco Emma; Paul Goodyer; Graham Lipkin; Julian P Midgley; Chris Ottolenghi; Aude Servais; Neveen A Soliman; Jess G Thoene; Elena N Levtchenko Journal: Kidney Int Date: 2016-06 Impact factor: 10.612
Authors: Martijn J Wilmer; Joost P Schoeber; Lambertus P van den Heuvel; Elena N Levtchenko Journal: Pediatr Nephrol Date: 2010-08-24 Impact factor: 3.714
Authors: Gema Ariceta; Enrique Lara; Juan A Camacho; Federico Oppenheimer; Julia Vara; Fernando Santos; Miguel Angel Muñoz; Carmen Cantarell; Marta Gil Calvo; Rafael Romero; Blanca Valenciano; Víctor García-Nieto; Maria José Sanahuja; José Crespo; Maria Luisa Justa; Adela Urisarri; Rafael Bedoya; Alberto Bueno; Antonio Daza; Juan Bravo; Francisco Llamas; Luis Antonio Jiménez Del Cerro Journal: Nephrol Dial Transplant Date: 2014-10-26 Impact factor: 5.992
Authors: Mohamed A Elmonem; Koenraad R Veys; Neveen A Soliman; Maria van Dyck; Lambertus P van den Heuvel; Elena Levtchenko Journal: Orphanet J Rare Dis Date: 2016-04-22 Impact factor: 4.123
Authors: Francesco Emma; Giovanni Montini; Marco Pennesi; Licia Peruzzi; Enrico Verrina; Bianca Maria Goffredo; Fabrizio Canalini; David Cassiman; Silvia Rossi; Elena Levtchenko Journal: Cells Date: 2022-06-04 Impact factor: 7.666
Authors: Francesco Bellomo; Ester De Leo; Anna Taranta; Laura Giaquinto; Gianna Di Giovamberardino; Sandro Montefusco; Laura Rita Rega; Anna Pastore; Diego Luis Medina; Diego Di Bernardo; Maria Antonietta De Matteis; Francesco Emma Journal: Int J Mol Sci Date: 2021-11-27 Impact factor: 5.923
Authors: Nina O'Connell; Jun Oh; Klaus Arbeiter; Anja Büscher; Dieter Haffner; Jessica Kaufeld; Christine Kurschat; Christoph Mache; Dominik Müller; Ludwig Patzer; Lutz T Weber; Burkhard Tönshoff; Marcus Weitz; Katharina Hohenfellner; Lars Pape Journal: Front Med (Lausanne) Date: 2022-04-25